Lake Street Lowers Tela Bio Price Target to $3 Amid Q3 Results Shortfall
Lake Street lowered the firm's price target on Tela Bio to $3 from $6 and keeps a Buy rating on the shares following Q3 results that "were short of the Street" and 2025 and 2026 guidance that was down on prolonged sales force disruption. The firm believes shares could be range bound in the near-term, but also thinks the recapped balance sheet and reset outlook will "provide the team an opportunity to exceed expectations," the analyst tells investors.
